AccessMyLibrary provides FREE access to over 30 million articles from top publications available through your library.
Create a link to this page
Copy and paste this link tag into your Web page or blog:
2001 MAR 14 - (NewsRx.com & NewsRx.net) --
by N.R. Saltmarsh, staff medical writer -- Scientists have identified adenovirus vectors as useful carriers for gene therapy of pituitary diseases, but were uncertain how long the treatment method would be effective.
In a recent study, T.D. Southgate and colleagues measured tissue levels of therapeutic genetic material over three months to determine both the longevity of the treatment effect and its potential safety. They found that genetic material could be observed in the pituitary three months later, though in decreasing amounts, and that pituitary hormones were not adversely affected.
After using an adenovirus vector to deliver herpes simplex virus type 1 thymidine kinase (HSV1-TK) to the anterior pituitary (AP) gland, the research team measured HSV1-TK expression in the pituitary at three days, 14 days, and one, two, and three months.
They noted a reduction in HSV1-TK expression over time, though HSV1-TK was seen even at three months ("Long-term transgene expression within the anterior pituitary gland in situ: Impact on circulating hormone levels, cellular and antibody-mediated immune responses," Endocrinology, 2001;142(1):464-476).
The most prominent potential side effect was an immune response to the virus, which peaked at day 14, reported Southgate and associates. There was no lasting change in pituitary hormone levels.
...Source: HighBeam Research, Adenovirus Delivery Of Gene Therapy Appears Safe.(for treatment of...